Full Breakdown
Maternal RSV Vaccine Programme Cuts Newborn ICU Admissions by Half in England
8/14/2026, 1:16:11 AM
Core Event
The UK Health Security Agency (UKHSA) annual report, published on 13 August 2026, documented a roughly 50 % decline in intensive-care admissions of infants under six months with confirmed respiratory syncytial virus (RSV) infection during the 2025-26 winter season. Across the 20 NHS trusts participating in the SARI Watch sentinel surveillance, 63 infants were admitted to intensive-care units (ICU) or high-dependency units (HDU) in 2025-26, compared with 131 admissions in the same trusts during the 2024-25 season.
Background & Context
RSV infects about 90 % of children by their second birthday and is the leading cause of bronchiolitis, a viral inflammation of the small airways that can require hospitalisation and, in severe cases, intensive-care support. The NHS introduced a maternal RSV vaccination programme in September 2024, offering a single dose to pregnant women from 28 weeks gestation onward. The vaccine is intended to boost maternal antibodies, which cross the placenta to protect newborns during their most vulnerable early months.
Data & Statistics
- ICU/HDU admissions: 63 infants (2025-26) vs. 131 infants (2024-25) – a 52 % reduction.
- Vaccine uptake: 61.7 % of women who gave birth between March 2025 and February 2026 received the RSV vaccine.
- Protection estimates: A UKHSA study presented at the ESCMID conference in 2025 reported that a single maternal dose provides over 80 % protection against RSV-related hospital admission. A separate cohort tracking nearly 300 000 infants found babies born to vaccinated mothers were up to 85 % less likely to be hospitalised with RSV.
- Seasonal pattern: The 2025-26 RSV season began rising in early November, peaked in December (weeks 49-52), and was shorter and less intense than previous winters.
Official Statements & Responses
- Dr Conall Watson, Immunisation Consultant, UKHSA, noted that intensive-care admissions have been halved since the maternal programme began and that A&E bronchiolitis attendances have also declined.
- Yvette Cooper, Secretary for State for Health and Social Care, highlighted the programme’s focus on maternity and child health and praised the high uptake.
- Caroline Temmink, NHS Director of Vaccinations, described the analysis as “fantastic news,” attributing the reduction in severe RSV cases to the vaccine’s effectiveness.
- Ashifa Trivedi, Neonatal Pharmacist, Evelina London Children’s Hospital, called the findings “really encouraging,” emphasizing the benefit for families and paediatric services.
Why It Matters / Impact
The halving of newborn ICU admissions translates into fewer infants requiring invasive respiratory support, reduced strain on intensive-care capacity, and lower overall healthcare costs during winter. By preventing severe RSV disease, the programme also lessens the emotional and financial burden on families. The concurrent decline in A&E bronchiolitis attendances suggests broader community benefits.
Timeline
- September 2024: Launch of the NHS maternal RSV vaccination programme.
- Winter 2024-25: 131 infants under six months admitted to ICU/HDU with RSV (baseline).
- Winter 2025-26: 63 infants admitted; peak RSV activity delayed to early November, peaking in December.
- 13 August 2026: UKHSA publishes annual report confirming 50 % reduction and 61.7 % vaccine uptake among birthing women.
What’s Next
The UK government and NHS England have urged local integrated care boards to maintain robust winter plans that prioritize vaccination uptake and equitable access. Ongoing surveillance will monitor RSV activity and vaccine impact in subsequent seasons.
